Navigation Links
Zimmer Announces Expiration of Deferred Prosecution Agreement
Date:3/30/2009

WARSAW, Ind., March 30 /PRNewswire-FirstCall/ -- Zimmer Holdings, Inc. (NYSE: ZMH; SWX: ZMH), a leader in the orthopaedic industry, today announced that the Deferred Prosecution Agreement (DPA) with the United States Attorney's Office for the District of New Jersey had expired as scheduled. The Company will no longer be subject to oversight by the monitor appointed under the DPA.

During the past 18 months, the Company has complied fully with the letter and spirit of the DPA and has made significant enhancements to its compliance structure and processes. The Company's enhanced corporate compliance program addresses how the Company is to interact with physician collaborators, managing potential or perceived conflicts of interest inherent in consulting relationships while preserving the best elements of collaboration that drive innovation in medical devices and services.

"While the expiration of the DPA is an important milestone, the Company remains committed to operating ethically and transparently on a global basis to preserve the trust required for productive, professional collaboration that ultimately benefits patients," said David Dvorak, Zimmer President and CEO.

The Company expects to remain subject to the terms of a Corporate Integrity Agreement it entered into with the Office of Inspector General of the Department of Health and Human Services until September 2012.

About Zimmer Holdings, Inc.

Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer designs, develops, manufactures and markets orthopaedic reconstructive, spinal and trauma devices, dental implants, and related surgical products. Zimmer has operations in more than 25 countries around the world and sells products in more than 100 countries. Zimmer's 2008 sales were approximately $4.1 billion. The Company is supported by the efforts of approximately 8,500 employees worldwide.

For more information about Zimmer, visit www.zimmer.com

Zimmer Safe Harbor Statement

This press release contains forward-looking statements within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 based on current expectations, estimates, forecasts and projections about the orthopaedics industry, management's beliefs and assumptions made by management. Forward-looking statements may be identified by the use of forward-looking terms such as "may," "will," "expects," "believes," "anticipates," "plans," "estimates," "projects," "assumes," "guides," "targets," "forecasts," and "seeks" or the negative of such terms or other variations on such terms or comparable terminology. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that could cause actual outcomes and results to differ materially. For a list and description of such risks and uncertainties, see our periodic reports filed with the U.S. Securities and Exchange Commission. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be set forth in our periodic reports. Readers of this document are cautioned not to place undue reliance on these forward-looking statements, since, while we believe the assumptions on which the forward-looking statements are based are reasonable, there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary statement is applicable to all forward-looking statements contained in this document.


'/>"/>
SOURCE Zimmer Holdings, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Zimmer Holdings Names Marc Casper to Board of Directors
2. Nyer Medical Appoints Sandra Zimmerman as Chief Financial Officer
3. Zimmer Presents Trabecular Metal Technology Experience at AAOS Annual Meeting
4. Zimmer Reports Fourth Quarter and 2008 Financial Results
5. Hip Replacement Patients at Possible Risk, Cleveland Law Firm Adds Zimmer Durom Cup Lawsuit Info on SpangLaw.com
6. Zimmer Holdings Announces Live Audio Webcast and Conference Call of Fourth Quarter and Full-Year 2008 Results
7. Zimmer Holdings Names Betsy Bernard to Board of Directors
8. Zimmer Holdings to Present at 27th Annual JP Morgan Healthcare Conference
9. Zimmer Holdings Names Jeffery A. McCaulley President, Zimmer Reconstructive
10. Zimmer Holdings to Present at Credit Suisse 2008 Healthcare Conference
11. Zimmer Holdings to Collaborate with the American Orthopaedic Association for Funding Post-Graduate Medical Education
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... ... broad access to life-saving drugs and rewarding the innovators who develop those drugs often ... , That was the message from Dana Goldman, PhD, Leonard D. Schaeffer Chair and ... who served as the keynote speaker for Western University of Health Sciences’ Ray Symposium ...
(Date:4/21/2017)... , ... April 21, 2017 , ... ... Christopher Salas-Wright finds that youth violence is declining—and at noteworthy rates. Between 2002 ... proportion of young people involved in violence in the United States. The study, ...
(Date:4/21/2017)... ... April 21, 2017 , ... Evoke Therapy Programs , ... kicked off its 4th annual Forum for Innovative Treatment Solutions (FITS), which runs ... Therapy for Mental Health and Addiction.” , FITS’ 2017 keynote presenters will ...
(Date:4/21/2017)... ... April 21, 2017 , ... Young Asset Protection, ... to communities throughout the greater Pittsburgh metropolitan region, is joining forces with the ... bicycles for differently-abled children. , Variety the Children’s Charity is a national organization ...
(Date:4/21/2017)... ... April 21, 2017 , ... The adage “Show, don’t tell” applies ... project in the company’s esteemed VISION House demonstration project series. Manifesting the concept of ... of resources they need to live affordably and abundantly without unduly taxing the resources ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017   ZappRx, Inc ., a digital ... prescribing process, today announced it closed $25 million in Series ... capital firm based in Seattle that ... Partners . The Series B round included participation from ... 2014, and GV (formerly Google Ventures). As part ...
(Date:4/20/2017)... April 20, 2017 Research and Markets ... Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key ... to their offering. ... global pharmacogenomics market was valued at US$ 7,167.6 Mn in ... 2024, expanding at a CAGR of 5.6% from 2016 to ...
(Date:4/20/2017)... April 20, 2017 NeuroVive Pharmaceutical AB ... announced positive preclinical results demonstrating anti-fibrotic effects ... non-alcoholic steatohepatitis (NASH), in an additional well-validated ... NV556 has previously shown similar anti-fibrotic effects ... NeuroVive,s scientists present novel data demonstrating anti-fibrotic ...
Breaking Medicine Technology: